Abstract
Background: Irritable bowel syndrome is a chronic continuous or remittent gastrointestinal illness characterized by frequent unexplained symptoms that include abdominal pain, bloating, and bowel disturbance, in our country, no study has been conducted using the Ispaghula husk and oxyphenonium bromide for the treatment of IBS patients. Objectives: To compare the efficacy of treatment with Ispaghula husk and Oxyphenonium bromide. Methods: Total sixty patients diagnosed clinically as irritable bowel syndrome irrespective of subtype who fulfilled the Rome II criteria were included equally into two groups-Group-I (Ispaghula group) & Group-II (Oxyphenonium group). In Group-I patients were given 30gm of Ispaghula husk at night daily and in Group-II patients were given 5mg of oxyphenonium bromide. After six weeks the clinical parameters of both the groups recorded in the case record forms were taken for analysis. Results: The mean age of the patients in the Group- I were 33.4±11.9 yrs and that of the patients in the Group-II were 31.0±17.5 yrs. Male and female ratio in group I was 14:1 and in group II was 23:7. Most of the patients were recorded in the age group of 26-30 in both groups. Symptom free patients were graded in 16.7% patients in Group-I and in 20% patients in Group- II. No improvement was occurred in 16.7% patients in Group-I and in 10% patients in Group-II. Conclusions: Ispaghula husk shows the better efficacy to improve the symptoms of IBS like abdominal pain or discomfort and sense of well being than Oxyphenonium bromide. Oxephenonium bromide shows the better efficacy to decrease the stool frequency from base line than Ispaghula husk. DOI: 10.3329/bsmmuj.v3i1.5506 BSMMU J 2010; 3(1): 3-8
Highlights
Irritable bowel syndrome is a chronic continuous or remittent functional gastrointestinal disorders characterized by frequent unexplained symptoms that include abdominal pain, bloating, and bowel disturbance, which may be either diarrhea or constipation or an errative bowel habit that has features of both[1]
Thirty adults patients diagnosed clinically as irritable bowel syndrome irrespective of subtype who fulfilled the Rome II criteria were included in this group
Abdominal pain or discomfort was improved in 23(76.7%) patients in group-I and in 20 (66%) in group-II
Summary
Irritable bowel syndrome is a chronic continuous or remittent functional gastrointestinal disorders characterized by frequent unexplained symptoms that include abdominal pain, bloating, and bowel disturbance, which may be either diarrhea or constipation or an errative bowel habit that has features of both[1].IBS is remarkably prevalent in the general population, affecting approximately 10-15% of persons in the Western world. Irritable bowel syndrome is a chronic continuous or remittent functional gastrointestinal disorders characterized by frequent unexplained symptoms that include abdominal pain, bloating, and bowel disturbance, which may be either diarrhea or constipation or an errative bowel habit that has features of both[1]. Irritable bowel syndrome is a chronic continuous or remittent gastrointestinal illness characterized by frequent unexplained symptoms that include abdominal pain, bloating, and bowel disturbance, in our country, no study has been conducted using the Ispaghula husk and oxyphenonium bromide for the treatment of IBS patients. In Group-I patients were given 30gm of Ispaghula husk at night daily and in Group-II patients were given 5mg of oxyphenonium bromide. Conclusions: Ispaghula husk shows the better efficacy to improve the symptoms of IBS like abdominal pain or discomfort and sense of well being than Oxyphenonium bromide. Oxephenonium bromide shows the better efficacy to decrease the stool frequency from base line than Ispaghula husk
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
